Form D — Kestrel Therapeutics Inc.
0001853373-25-000001 · filed Feb 21, 2025
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Total offering
- $16,000,000
- Total sold
- $8,000,000
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Kestrel Therapeutics Inc.
- CIK
- 1853373
- Entity
- Corporation
- Jurisdiction
- DELAWARE
- Year incorporated
- 2020
- Address
- Attn: Pagliuca Harvard Life Lab
Boston, MA 02134 - Phone
- 617-460-3772
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Frank G. Haluska · Executive OfficerBoston, MA Find on LinkedIn ↗
-
Denis Patrick · DirectorBoston, MA Find on LinkedIn ↗
-
Omar Khalil · DirectorBoston, MA Find on LinkedIn ↗
-
Andrew Phillips · DirectorBoston, MA Find on LinkedIn ↗
-
Nicholas Saccomano · DirectorBoston, MA Find on LinkedIn ↗
-
Barbara Sosnowski · DirectorBoston, MA Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗